Showing results (301-310 of 319) with videos related to
Sort By:
Pageof 32
Scientific Reports|August 23, 2019
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigationsPatrizia Nanni, Lorena Landuzzi, Maria Cristina Manara, et al.The Oncologist|December 6, 2008
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practiceDaniele Santini, Fotios Loupakis, Bruno Vincenzi, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 24, 2009
HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infectionEmanuele Fanales-Belasio, Sonia Moretti, Valeria Fiorelli, et al.Cancers|July 30, 2020
<i>TP53</i> Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard ChemotherapyFrancesco Graziano, Nicholas W Fischer, Irene Bagaloni, et al.Frontiers in Immunology|April 27, 2026
Therapeutic HIV-1 Tat vaccination promotes durable immune reconstitution and reservoir reduction in ART-treated adults with clade C infection: a 12-year follow-up studyOrietta Picconi, Cecilia Sgadari, Antonella Tripiciano, et al.Frontiers in Immunology|March 1, 2019
Continued Decay of HIV Proviral DNA Upon Vaccination With HIV-1 Tat of Subjects on Long-Term ART: An 8-Year Follow-Up StudyCecilia Sgadari, Paolo Monini, Antonella Tripiciano, et al.Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|May 7, 2020
Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumabAnnamaria Ruzzo, Francesco Graziano, Irene Bagaloni, et al.Cells|April 12, 2024
CD99 Expression and Prognostic Impact in Glioblastoma: A Single-Center Cohort StudyAndrea Rocca, Fabiola Giudici, Carmine Antonio Donofrio, et al.Retrovirology|June 10, 2016
HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trialBarbara Ensoli, Maphoshane Nchabeleng, Fabrizio Ensoli, et al.Vaccine|February 12, 2009
Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-upOlimpia Longo, Antonella Tripiciano, Valeria Fiorelli, et al.Pageof 32